PL3606909T3 - Sól sodowa N-((1,2,3,5,6,7-heksahydro-s-indacen-4-ylo)karbamoilo)-1-izopropylo-1H-pirazolo-3-sulfonamidu - Google Patents
Sól sodowa N-((1,2,3,5,6,7-heksahydro-s-indacen-4-ylo)karbamoilo)-1-izopropylo-1H-pirazolo-3-sulfonamiduInfo
- Publication number
- PL3606909T3 PL3606909T3 PL19721230T PL19721230T PL3606909T3 PL 3606909 T3 PL3606909 T3 PL 3606909T3 PL 19721230 T PL19721230 T PL 19721230T PL 19721230 T PL19721230 T PL 19721230T PL 3606909 T3 PL3606909 T3 PL 3606909T3
- Authority
- PL
- Poland
- Prior art keywords
- indacen
- hexahydro
- sulfonamide
- pyrazole
- carbamoyl
- Prior art date
Links
- MTOUOUSKXWSTAX-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-(1-propan-2-ylpyrazol-3-yl)sulfonylurea Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)NS(=O)(=O)C1=NN(C=C1)C(C)C MTOUOUSKXWSTAX-UHFFFAOYSA-N 0.000 title 1
- 159000000000 sodium salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806578.9A GB201806578D0 (en) | 2018-04-23 | 2018-04-23 | Novel compound |
| PCT/EP2019/060311 WO2019206871A1 (en) | 2018-04-23 | 2019-04-23 | A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
| EP19721230.1A EP3606909B1 (en) | 2018-04-23 | 2019-04-23 | A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3606909T3 true PL3606909T3 (pl) | 2020-11-16 |
Family
ID=62236309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19721230T PL3606909T3 (pl) | 2018-04-23 | 2019-04-23 | Sól sodowa N-((1,2,3,5,6,7-heksahydro-s-indacen-4-ylo)karbamoilo)-1-izopropylo-1H-pirazolo-3-sulfonamidu |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10973803B2 (pl) |
| EP (2) | EP3606909B1 (pl) |
| JP (1) | JP7382958B2 (pl) |
| KR (1) | KR20210005589A (pl) |
| CN (1) | CN112020495B (pl) |
| AR (1) | AR114827A1 (pl) |
| AU (1) | AU2019257973A1 (pl) |
| BR (1) | BR112020021650A2 (pl) |
| CA (1) | CA3097832A1 (pl) |
| CY (1) | CY1123260T1 (pl) |
| DK (1) | DK3606909T3 (pl) |
| ES (1) | ES2811228T3 (pl) |
| GB (1) | GB201806578D0 (pl) |
| HR (1) | HRP20201263T1 (pl) |
| HU (1) | HUE050369T2 (pl) |
| LT (1) | LT3606909T (pl) |
| MA (2) | MA51082A (pl) |
| MD (1) | MD3606909T2 (pl) |
| ME (1) | ME03822B (pl) |
| MX (1) | MX2020011196A (pl) |
| PL (1) | PL3606909T3 (pl) |
| PT (1) | PT3606909T (pl) |
| RS (1) | RS60646B1 (pl) |
| SI (1) | SI3606909T1 (pl) |
| SM (1) | SMT202000448T1 (pl) |
| TW (1) | TW201943704A (pl) |
| UY (1) | UY38186A (pl) |
| WO (1) | WO2019206871A1 (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| BR112019024831A2 (pt) | 2017-05-24 | 2020-06-09 | The University Of Queensland | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| CA3071150A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| BR112020002906A2 (pt) | 2017-08-15 | 2020-08-04 | Inflazome Limited | novos compostos de sulfonamida-carboxamida |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| RU2020115098A (ru) | 2017-11-09 | 2021-12-10 | Инфлазоум Лимитед | Соединения новых сульфонамидкарбоксамидов |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| EP3759102A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US12168653B2 (en) | 2018-03-02 | 2024-12-17 | Inflazome Limited | Sulfonamide derivates as NLRP3 inhibitors |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019166628A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| PE20211049A1 (es) | 2018-07-20 | 2021-06-04 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
| KR20210034596A (ko) | 2018-07-20 | 2021-03-30 | 에프. 호프만-라 로슈 아게 | 인터류킨-1 활성의 저해제로서 술폰이미드아미드 화합물 |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2023500925A (ja) * | 2019-11-07 | 2023-01-11 | インフレイゾーム リミテッド | 神経炎症または炎症性脳疾患の処置および予防 |
| JP2023501319A (ja) * | 2019-11-07 | 2023-01-18 | インフレイゾーム リミテッド | 神経変性疾患の処置および予防 |
| EP4054564A1 (en) * | 2019-11-07 | 2022-09-14 | Inflazome Limited | Treatment of autoinflammatory disorders |
| WO2021089781A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
| GB201916237D0 (en) * | 2019-11-07 | 2019-12-25 | Inflazome Ltd | Novel treatment |
| WO2021089776A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment and prevention of a traumatic brain disorder |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4802908A (en) * | 1987-01-22 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2-(1H)-pyrazinones |
| WO2001019390A1 (en) * | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| CN104023729A (zh) * | 2011-09-02 | 2014-09-03 | 协和发酵麒麟株式会社 | 趋化因子受体活性调节剂 |
| AU2016222278B2 (en) | 2015-02-16 | 2020-07-09 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| ES2855732T3 (es) | 2016-04-18 | 2021-09-24 | Novartis Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
-
2018
- 2018-04-23 GB GBGB1806578.9A patent/GB201806578D0/en not_active Ceased
-
2019
- 2019-04-23 MA MA051082A patent/MA51082A/fr unknown
- 2019-04-23 JP JP2020557902A patent/JP7382958B2/ja active Active
- 2019-04-23 RS RS20200936A patent/RS60646B1/sr unknown
- 2019-04-23 CN CN201980026640.0A patent/CN112020495B/zh active Active
- 2019-04-23 WO PCT/EP2019/060311 patent/WO2019206871A1/en not_active Ceased
- 2019-04-23 MD MDE20200181T patent/MD3606909T2/ro unknown
- 2019-04-23 ME MEP-2020-173A patent/ME03822B/me unknown
- 2019-04-23 UY UY0001038186A patent/UY38186A/es not_active Application Discontinuation
- 2019-04-23 SM SM20200448T patent/SMT202000448T1/it unknown
- 2019-04-23 MX MX2020011196A patent/MX2020011196A/es unknown
- 2019-04-23 TW TW108114167A patent/TW201943704A/zh unknown
- 2019-04-23 MA MA48051A patent/MA48051B1/fr unknown
- 2019-04-23 KR KR1020207030023A patent/KR20210005589A/ko not_active Ceased
- 2019-04-23 AU AU2019257973A patent/AU2019257973A1/en not_active Abandoned
- 2019-04-23 EP EP19721230.1A patent/EP3606909B1/en active Active
- 2019-04-23 DK DK19721230.1T patent/DK3606909T3/da active
- 2019-04-23 HU HUE19721230A patent/HUE050369T2/hu unknown
- 2019-04-23 EP EP20176198.8A patent/EP3722281A1/en not_active Withdrawn
- 2019-04-23 SI SI201930005T patent/SI3606909T1/sl unknown
- 2019-04-23 LT LTEP19721230.1T patent/LT3606909T/lt unknown
- 2019-04-23 HR HRP20201263TT patent/HRP20201263T1/hr unknown
- 2019-04-23 PT PT197212301T patent/PT3606909T/pt unknown
- 2019-04-23 AR ARP190101056A patent/AR114827A1/es not_active Application Discontinuation
- 2019-04-23 BR BR112020021650-0A patent/BR112020021650A2/pt not_active Application Discontinuation
- 2019-04-23 CA CA3097832A patent/CA3097832A1/en active Pending
- 2019-04-23 PL PL19721230T patent/PL3606909T3/pl unknown
- 2019-04-23 ES ES19721230T patent/ES2811228T3/es active Active
-
2020
- 2020-04-16 US US16/850,978 patent/US10973803B2/en active Active
- 2020-08-12 CY CY20201100756T patent/CY1123260T1/el unknown
-
2021
- 2021-03-09 US US17/196,956 patent/US20210315862A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3606909T3 (pl) | Sól sodowa N-((1,2,3,5,6,7-heksahydro-s-indacen-4-ylo)karbamoilo)-1-izopropylo-1H-pirazolo-3-sulfonamidu | |
| IL275761A (en) | Benzamide compounds | |
| PH12018502136A1 (en) | Heterocyclic amides useful as protein modulators | |
| PH12020500673A1 (en) | Compounds | |
| MX379169B (es) | Amidas heterocíclicas útiles como moduladores de proteínas. | |
| JOP20200059A1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| CA196171S (en) | Head strap | |
| IL290692A (en) | Salt | |
| CA190437S (en) | Face mask | |
| SG11202112276RA (en) | Novel peptide compound or pharmaceutically acceptable salt thereof | |
| PL3317272T3 (pl) | Chwastobójczo skuteczne pochodne N-(1,3,4-oksadiazol-2-ilo)arylokarboksyamidowe | |
| IL260665B (en) | Improved process for the preparation of osimertinib (azd9291) or its salt and "azd9291 aniline" or its salt | |
| IL288575A (en) | N-(pyrid-3-yl)carboxamides fungicides | |
| IL282905A (en) | Cycloalkane-1, 3-diamine derivative | |
| CA190436S (en) | Face mask | |
| IL276196B1 (en) | Synthesis of 5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)thio]-thiazole | |
| WO2017191619A3 (en) | A process for the preparation of a salt of sacubitril and valsartan | |
| LT3592734T (lt) | (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska | |
| ZA202110350B (en) | 2-phenoxy-pyrimidine derivatives as herbicidal compounds | |
| GB202110403D0 (en) | Ulodesine Salt | |
| PL3911633T3 (pl) | Podstawione herbicydy N-tetrazoliloarylokarboksyamidowe | |
| AR101109A1 (es) | Forma polimórfica del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina | |
| GB201904190D0 (en) | Salt | |
| GB201906171D0 (en) | Di-peptides | |
| GB202104272D0 (en) | Salt |